Skip to main content
PMC home page
Gut logoLink to Gut
. 1990 Nov;31(11):1271–1276. doi: 10.1136/gut.31.11.1271

Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.

L Staerk Laursen 1, M Stokholm 1, K Bukhave 1, J Rask-Madsen 1, K Lauritsen 1
PMCID: PMC1378698  PMID: 2253912

Abstract

To compare the disposition of 5-aminosalicylic acid (5-ASA) and its acetylated metabolite during treatment with olsalazine and mesalazine, 14 patients with inactive ulcerative colitis were randomly assigned to olsalazine (1 g twice daily) and the mesalazines, Asacol (800 + 400 + 800 mg daily), Pentasa (750 + 500 + 750 mg daily), and Salofalk (750 + 500 + 750 mg daily) in a crossover design trial so that all received each drug for seven days. Intraluminal colonic concentrations of 5-ASA were estimated after five days by the method of equilibrium in vivo dialysis of faeces. A predose serum sample and a 24 hour urine collection were obtained on day seven. The 5-ASA and acetyl-5-aminosalicylic acid (Ac-5-ASA) values were determined by high performance liquid chromatography. Olsalazine almost doubled the colonic concentrations (mean 23.7 (SEM) (1.9) mmol/l) of its therapeutically active ingredient (5-ASA) compared with equimolar doses of Pentasa (12.6 (2.2) mmol/l; p less than 0.0003) and Salofalk (15.0 (2.0) mmol/l; p less than 0.003). At the same time, olsalazine treatment was associated with lower serum concentrations and urinary excretions (p less than 0.05) of 5-ASA and Ac-5-ASA compared with the mesalazine preparations. The low systemic load of 5-ASA provided by olsalazine reduces the potential risk of nephrotoxicity during long term treatment.

Full text

PDF
1271

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azad Khan A. K., Howes D. T., Piris J., Truelove S. C. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut. 1980 Mar;21(3):232–240. doi: 10.1136/gut.21.3.232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Azad Khan A. K., Piris J., Truelove S. C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977 Oct 29;2(8044):892–895. doi: 10.1016/s0140-6736(77)90831-5. [DOI] [PubMed] [Google Scholar]
  3. Binder V., Both H., Hansen P. K., Hendriksen C., Kreiner S., Torp-Pedersen K. Incidence and prevalence of ulcerative colitis and Crohn's disease in the County of Copenhagen, 1962 to 1978. Gastroenterology. 1982 Sep;83(3):563–568. [PubMed] [Google Scholar]
  4. Calder I. C., Funder C. C., Green C. R., Ham K. N., Tange J. D. Nephrotoxic lesions from 5-aminosalicylic Acid. Br Med J. 1972 Jan 15;1(5793):152–154. doi: 10.1136/bmj.1.5793.152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Calder I. C., Williams P. J., Woods R. A., Funder C. C., Green C. R., Ham K. N., Tange J. D. Nephrotoxicity and molecular structure. Xenobiotica. 1975 May;5(5):303–307. doi: 10.3109/00498257509052064. [DOI] [PubMed] [Google Scholar]
  6. Campieri M., Lanfranchi G. A., Bazzocchi G., Brignola C., Sarti F., Franzin G., Battocchia A., Labo G., Dal Monte P. R. Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet. 1981 Aug 8;2(8241):270–271. doi: 10.1016/s0140-6736(81)90523-7. [DOI] [PubMed] [Google Scholar]
  7. Christensen L. A., Slot O., Sanchez G., Boserup J., Rasmussen S. N., Bondesen S., Hansen S. H., Hvidberg E. F. Release of 5-aminosalicylic acid from Pentasa during normal and accelerated intestinal transit time. Br J Clin Pharmacol. 1987 Mar;23(3):365–369. doi: 10.1111/j.1365-2125.1987.tb03061.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dew M. J., Ebden P., Kidwai N. S., Lee G., Evans B. K., Rhodes J. Comparison of the absorption and metabolism of sulphasalazine and acrylic-coated 5-amino salicylic acid in normal subjects and patients with colitis. Br J Clin Pharmacol. 1984 Apr;17(4):474–476. doi: 10.1111/j.1365-2125.1984.tb02375.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dew M. J., Harries A. D., Evans N., Evans B. K., Rhodes J. Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth. Br Med J (Clin Res Ed) 1983 Jul 2;287(6384):23–24. doi: 10.1136/bmj.287.6384.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Dew M. J., Hughes P. J., Lee M. G., Evans B. K., Rhodes J. An oral preparation to release drugs in the human colon. Br J Clin Pharmacol. 1982 Sep;14(3):405–408. doi: 10.1111/j.1365-2125.1982.tb01999.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Dew M. J., Hughes P., Harries A. D., Williams G., Evans B. K., Rhodes J. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. Br Med J (Clin Res Ed) 1982 Oct 9;285(6347):1012–1012. doi: 10.1136/bmj.285.6347.1012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Dew M. J., Ryder R. E., Evans N., Evans B. K., Rhodes J. Colonic release of 5-amino salicylic acid from an oral preparation in active ulcerative colitis. Br J Clin Pharmacol. 1983 Aug;16(2):185–187. doi: 10.1111/j.1365-2125.1983.tb04983.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Goldman P. Will there be a next generation of sulfasalazine? Gastroenterology. 1982 Nov;83(5):1138–1141. [PubMed] [Google Scholar]
  14. Haagen Nielsen O., Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal instillation in man. Br J Clin Pharmacol. 1983 Dec;16(6):738–740. doi: 10.1111/j.1365-2125.1983.tb02254.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hardy J. G., Healey J. N., Lee S. W., Reynolds J. R. Gastrointestinal transit of an enteric-coated delayed-release 5-aminosalicylic acid tablet. Aliment Pharmacol Ther. 1987 Jun;1(3):209–216. doi: 10.1111/j.1365-2036.1987.tb00620.x. [DOI] [PubMed] [Google Scholar]
  16. Ireland A., Mason C. H., Jewell D. P. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut. 1988 Jun;29(6):835–837. doi: 10.1136/gut.29.6.835. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Klotz U., Maier K. E., Fischer C., Bauer K. H. A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics. Arzneimittelforschung. 1985;35(3):636–639. [PubMed] [Google Scholar]
  18. Lauritsen K., Hansen J., Ryde M., Rask-Madsen J. Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis. Gastroenterology. 1984 Jun;86(6):1496–1500. [PubMed] [Google Scholar]
  19. Lauritsen K., Laursen L. S., Bukhave K., Rask-Madsen J. Use of colonic eicosanoid concentrations as predictors of relapse in ulcerative colitis: double blind placebo controlled study on sulphasalazine maintenance treatment. Gut. 1988 Oct;29(10):1316–1321. doi: 10.1136/gut.29.10.1316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lauritsen K., Staerk Laursen L., Bukhave K., Rask-Madsen J. Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis. Gut. 1988 Jul;29(7):974–982. doi: 10.1136/gut.29.7.974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Meyers S., Sachar D. B., Present D. H., Janowitz H. D. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Gastroenterology. 1987 Dec;93(6):1255–1262. doi: 10.1016/0016-5085(87)90253-8. [DOI] [PubMed] [Google Scholar]
  22. Mulder C. J., Tytgat G. N., Weterman I. T., Dekker W., Blok P., Schrijver M., van der Heide H. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology. 1988 Dec;95(6):1449–1453. doi: 10.1016/s0016-5085(88)80061-1. [DOI] [PubMed] [Google Scholar]
  23. Myers B., Evans D. N., Rhodes J., Evans B. K., Hughes B. R., Lee M. G., Richens A., Richards D. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut. 1987 Feb;28(2):196–200. doi: 10.1136/gut.28.2.196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Novis B. H., Korzets Z., Chen P., Bernheim J. Nephrotic syndrome after treatment with 5-aminosalicylic acid. Br Med J (Clin Res Ed) 1988 May 21;296(6634):1442–1442. doi: 10.1136/bmj.296.6634.1442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Peppercorn M. A., Goldman P. Distribution studies of salicylazosulfapyridine and its metabolites. Gastroenterology. 1973 Feb;64(2):240–245. [PubMed] [Google Scholar]
  26. Pieniaszek H. J., Jr, Bates T. R. Capacity-limited gut wall metabolism of 5-aminosalicylic acid, a therapeutically active metabolite of sulfasalazine, in rats. J Pharm Sci. 1979 Oct;68(10):1323–1325. doi: 10.1002/jps.2600681036. [DOI] [PubMed] [Google Scholar]
  27. Rasmussen S. N., Bondesen S., Hvidberg E. F., Hansen S. H., Binder V., Halskov S., Flachs H. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology. 1982 Nov;83(5):1062–1070. [PubMed] [Google Scholar]
  28. Rijk M. C., van Schaik A., van Tongeren J. H. Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds. Scand J Gastroenterol. 1988 Jan;23(1):107–112. doi: 10.3109/00365528809093858. [DOI] [PubMed] [Google Scholar]
  29. Riley S. A., Mani V., Goodman M. J., Herd M. E., Dutt S., Turnberg L. A. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut. 1988 May;29(5):669–674. doi: 10.1136/gut.29.5.669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Riley S. A., Mani V., Goodman M. J., Herd M. E., Dutt S., Turnberg L. A. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology. 1988 Jun;94(6):1383–1389. doi: 10.1016/0016-5085(88)90677-4. [DOI] [PubMed] [Google Scholar]
  31. Rutgeerts P. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group. Aliment Pharmacol Ther. 1989 Apr;3(2):183–191. [PubMed] [Google Scholar]
  32. Ryde E. M., Ahnfelt N. O. The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food. Eur J Clin Pharmacol. 1988;34(5):481–488. doi: 10.1007/BF01046706. [DOI] [PubMed] [Google Scholar]
  33. Sandberg-Gertzén H., Ryde M., Järnerot G. Absorption and excretion of a single 1-g dose of azodisal sodium in subjects with ileostomy. Scand J Gastroenterol. 1983 Jan;18(1):107–111. doi: 10.3109/00365528309181568. [DOI] [PubMed] [Google Scholar]
  34. Schroeder K. W., Tremaine W. J., Ilstrup D. M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987 Dec 24;317(26):1625–1629. doi: 10.1056/NEJM198712243172603. [DOI] [PubMed] [Google Scholar]
  35. Schröder H., Campbell D. E. Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther. 1972 Jul-Aug;13(4):539–551. doi: 10.1002/cpt1972134539. [DOI] [PubMed] [Google Scholar]
  36. Selby W. S., Barr G. D., Ireland A., Mason C. H., Jewell D. P. Olsalazine in active ulcerative colitis. Br Med J (Clin Res Ed) 1985 Nov 16;291(6506):1373–1375. doi: 10.1136/bmj.291.6506.1373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. WRONG O., METCALFE-GIBSON A., MORRISON R. B., NG S. T., HOWARD A. V. IN VIVO DIALYSIS OF FAECES AS A METHOD OF STOOL ANALYSIS. I. TECHNIQUE AND RESULTS IN NORMAL SUBJECTS. Clin Sci. 1965 Apr;28:357–375. [PubMed] [Google Scholar]
  38. van Hees P. A., Bakker J. H., van Tongeren J. H. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut. 1980 Jul;21(7):632–635. doi: 10.1136/gut.21.7.632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. van Hogezand R. A., van Hees P. A., van Gorp J. P., van Lier H. J., Bakker J. H., Wesseling P., van Haelst U. J., van Tongeren J. H. Double-blind comparison of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid suppositories in patients with idiopathic proctitis. Aliment Pharmacol Ther. 1988 Feb;2(1):33–40. doi: 10.1111/j.1365-2036.1988.tb00668.x. [DOI] [PubMed] [Google Scholar]
  40. von Mühlendahl K. E. Nephritis durch 5-Aminosalicylsäure. Dtsch Med Wochenschr. 1989 Feb 10;114(6):236–236. [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES